?

Cardiovascular Market Research Reports & Industry Analysis

Caused by heart and/or blood-vascular system disorders, cardiovascular (CDV) diseases kill almost 17 million people annually. The cardiovascular market can be divided the following key segments: cardiac surgery, cardiac rhythm management (abbreviated as CRM) and interventional cardiology. There is a wide range of products on offer in the market: defibrillators, introducers, catheters, pacemakers, among others.

The growth of the cardiovascular market is driven by the aging population, rising incidence of chronic CDV, innovations and technology advancements in the cardiovascular industry and constantly improving treatment capabilities. The USA is the largest cardiovascular market, with AstraZeneca , Merck & Co. , Bristol-Myers Squibb (BMS), Novartis , Sanofi-Aventis and Pfizerbeing amid the most prominent market participants.

Comprehensive assessment of the cardiovascular market at various geographical scales and over different time spans is provided in the research reports found under this catalogue. Data demand and supply trends, research and development activities, and leading market players are at hand in the reports. Moreover, future prospects for the market are disclosed in the research reports.

Found 406 publications
Prosthetic Heart Valves - Pipeline Review, 2015 US$ 4,000.00

Prosthetic Heart Valves - Pipeline Review, 2015 SUMMARY GlobalData's Medical Devices sector report, “Prosthetic Heart Valves - Pipeline Review, 2015' provides an overview of Prosthetic Heart Valves currently in pipeline stage. The report ...

Apr, 2015 309 pages
Diastolic Heart Failure Global Clinical Trials Review, H1, 2015 US$ 2,500.00

Diastolic Heart Failure Global Clinical Trials Review, H1, 2015 SUMMARY GlobalData's clinical trial report, “Diastolic Heart Failure Global Clinical Trials Review, H1, 2015' provides data on the Diastolic Heart Failure clinical trial ...

Apr, 2015 82 pages
MediPoint: Prosthetic Heart Valves - US Analysis and Market Forecasts US$ 4,450.00

MediPoint: Prosthetic Heart Valves - US Analysis and Market Forecasts SUMMARY The US prosthetic heart valves (PHV) market is a dynamic market that is expected to grow through 2020. ... patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015
MediPoint: Prosthetic Heart Valves - South America Analysis and Market Forecasts US$ 4,450.00

MediPoint: Prosthetic Heart Valves - South America Analysis and Market Forecasts SUMMARY The prosthetic heart valves (PHV) market in South America is a dynamic market that is expected to grow through 2020. This growth is ... patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015
MediPoint: Prosthetic Heart Valves - Global Analysis and Market Forecasts US$ 6,495.00

MediPoint: Prosthetic Heart Valves - Global Analysis and Market Forecasts SUMMARY The global prosthetic heart valves (PHV) market is a dynamic, billion-dollar market that is expected to grow ... patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015 253 pages
MediPoint: Prosthetic Heart Valves - Current and Future Players US$ 3,500.00

MediPoint: Prosthetic Heart Valves - Current and Future Players SUMMARY The global prosthetic heart valves (PHV) market is a dynamic, billion-dollar market that is saturated with ... applications. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015
MediPoint: Prosthetic Heart Valves - APAC Analysis and Market Forecasts US$ 4,450.00

MediPoint: Prosthetic Heart Valves - APAC Analysis and Market Forecasts SUMMARY The Asia-Pacific (APAC) prosthetic heart valves (PHV) market is a dynamic market that is expected to grow through 2020. ... patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015
MediPoint: Prosthetic Heart Valves - 5EU Analysis and Market Forecasts US$ 4,450.00

MediPoint: Prosthetic Heart Valves - 5EU Analysis and Market Forecasts SUMMARY The prosthetic heart valves (PHV) market in Europe is a dynamic market that is expected to grow through 2020. Recent advancements ... patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They ...

Feb, 2015
Global Cardiac Rhythm Management (CRM) Market Report: 2015 Edition US$ 800.00

Cardiac rhythm management (CRM) is a well-established segment of the cardiology devices market. CRM majorly consists of devices such ... . The report, “Global Cardiac Rhythm Management Market: 2015 Edition” analyzes the fundamentals and development of global cardiac rhythm management market globally and in the ...

Mar, 2015 46 pages
Endothelial Dysfunction Global Clinical Trials Review, H1, 2015 US$ 2,500.00

Endothelial Dysfunction Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Endothelial Dysfunction Global Clinical Trials Review, H1, 2015' provides data on the Endothelial Dysfunction clinical trial ...

Mar, 2015 84 pages
Opportunity in the Indian Cardiac Pacemaker Market - 2015; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast US$ 5,000.00

This report provides an insight into the Opportunity in the Cardiac Pacemaker current market scenario, structure and practices. In depth market ... players’ presence across products. Market practices include understanding the Cardiac Pacemaker market sets business, market trends, distribution practices and ...

Mar, 2015 45 pages
Global Cardiovascular Stent Industry 2014 Market Research Report US$ 2,850.00

... Stent Industry 2014 Market Research Report' was a professional and depth research report on Global Cardiovascular Stent industry that you would know ... analysis, investment feasibility analysis, and investment return analysis and Global Twin-screw Extruder industry. In a word, it was a depth research report ...

Nov, 2014 176 pages
Global Cardiovascular Catheter Guidewires Industry 2014 Market Research Report US$ 2,850.00

... Twin-screw Extruder industry. In a word, it was a depth research report on Global Cardiovascular Catheter Guidewires industry. And thanks to the support and assistance ... information; the second part mainly analyzed the Asia Cardiovascular Catheter Guidewires industry; the third part mainly analyzed the North ...

Nov, 2014 176 pages
Global Cardiovascular Balloon Catheters Industry 2014 Market Research Report US$ 2,850.00

... Twin-screw Extruder industry. In a word, it was a depth research report on Global Cardiovascular Balloon Catheters industry. And thanks to the support and assistance ... basic information; the second part mainly analyzed the Asia Cardiovascular Balloon Catheters industry; the third part mainly analyzed the North ...

Nov, 2014 176 pages
Global Cardiac Leads Industry 2014 Market Research Report US$ 2,850.00

... Leads Industry 2014 Market Research Report' was a professional and depth research report on Global Cardiac Leads industry that you would know the ... SWOT analysis, investment feasibility analysis, and investment return analysis and Global Twin-screw Extruder industry. In a word, it was a depth research report ...

Nov, 2014 176 pages
Global Cardiac Holter Monitor Industry 2014 Market Research Report US$ 2,850.00

... Monitor new project SWOT analysis, investment feasibility analysis, and investment return analysis and Global Twin-screw Extruder industry. In a word, it was a depth research report on Global Cardiac Holter Monitor industry. And thanks to the support and assistance from Cardiac Holter ...

Nov, 2014 176 pages
Global Cardiac Cannulae Industry 2014 Market Research Report US$ 2,850.00

... Cannulae Industry 2014 Market Research Report' was a professional and depth research report on Global Cardiac Cannulae industry that you would know ... SWOT analysis, investment feasibility analysis, and investment return analysis and Global Twin-screw Extruder industry. In a word, it was a depth research report ...

Nov, 2014 176 pages
Global Cardiac Ablation Catheters Industry 2014 Market Research Report US$ 2,850.00

... and Global Twin-screw Extruder industry. In a word, it was a depth research report on Global Cardiac Ablation Catheters industry. And thanks to the support and assistance from Cardiac Ablation Catheters industry chain related technical experts and marketing experts during Research ...

Nov, 2014 176 pages
Ischemic Cerebral Stroke - Pipeline Review, H2 2014 US$ 2,000.00

... Cerebral Stroke - Pipeline Review, H2 2014’, provides an overview of the Ischemic Cerebral Stroke’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemic Cerebral Stroke, complete with comparative analysis at various stages, therapeutics assessment ...

Nov, 2014 37 pages
Ventricular Septal Defect Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Ventricular Septal Defect Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Ventricular Septal Defect Global Clinical Trials Review, H2, 2014' provides data on the Ventricular Septal Defect clinical trial ...

Sep, 2014 57 pages
Venous (Vein) Thrombosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Venous (Vein) Thrombosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Venous (Vein) Thrombosis Global Clinical Trials Review, H2, 2014' provides data on the Venous (Vein) Thrombosis clinical trial ...

Sep, 2014 193 pages
Vasospastic Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Vasospastic Angina Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Vasospastic Angina Global Clinical Trials Review, H2, 2014' provides data on the Vasospastic Angina clinical trial ...

Sep, 2014 56 pages
Vascular Calcification Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Vascular Calcification clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vascular Calcification. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 58 pages
Unstable Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Unstable Angina clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Unstable Angina. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 109 pages
Thrombosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Thrombosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thrombosis. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 154 pages
Physician Views: New data for Novartis' LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market? US$ 695.00

... products, among the first in a new wave of medicines in late-stage development at Big Pharma for cardiovascular indications. Data from the PARADIGM-HF trial ... play a role in the company's price-setting calculus. Based on the new data, JP Morgan analyst Richard Vosser believes LCZ696 has 'multi-blockbuster ...

Restenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Restenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Restenosis. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 88 pages
Hot Flashes Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Hot Flashes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hot Flashes. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 109 pages
Hematoma Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Hematoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hematoma. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 62 pages
Heart Valve Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Heart Valve Disease Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Heart Valve Disease Global Clinical Trials Review, H2, 2014' provides data on the Heart Valve Disease clinical trial ...

Sep, 2014 71 pages
Heart Attack Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Heart Attack clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Heart Attack. It includes an overview of the trial numbers and their recruitment ...

Sep, 2014 78 pages
Giant Cell Arteritis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Giant Cell Arteritis Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Giant Cell Arteritis Global Clinical Trials Review, H2, 2014' provides data on the Giant Cell Arteritis clinical trial ...

Sep, 2014 70 pages
Endothelial Dysfunction Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Endothelial Dysfunction Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Endothelial Dysfunction Global Clinical Trials Review, H2, 2014' provides data on the Endothelial Dysfunction clinical trial ...

Sep, 2014 76 pages
Eisenmenger Syndrome Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Eisenmenger Syndrome Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Eisenmenger Syndrome Global Clinical Trials Review, H2, 2014' provides data on the Eisenmenger Syndrome clinical trial ...

Aug, 2014 81 pages
Edema Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Edema. It includes an overview of the trial numbers and their recruitment ...

Aug, 2014 78 pages
Diastolic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Diastolic Hypertension Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Diastolic Hypertension Global Clinical Trials Review, H2, 2014' provides data on the Diastolic Hypertension clinical trial ...

Aug, 2014 70 pages
Diabetic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Diabetic Hypertension Global Clinical Trials Review, H2, 2014 SUMMARY GlobalData's clinical trial report, “Diabetic Hypertension Global Clinical Trials Review, H2, 2014' provides data on the Diabetic Hypertension clinical trial ...

Aug, 2014 62 pages
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast and Market ... initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin ...

Jul, 2014 88 pages
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and Market ... fundamentally alter the ACS market, both medically and financially. Xarelto was approved in the EU for the prevention of non-valvular atrial ...

Jul, 2014 91 pages
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates ... market, both medically and financially. Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for ...

Jul, 2014 233 pages
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates ... as an overview on the competitive landscape. Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT ...

Jul, 2014 218 pages
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData ...

Jul, 2014 277 pages
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast and Market ... fundamentally alter the ACS market, both medically and financially. Evolocumab is a member of the emerging class of PCSK9 (proprotein convertase subtilisin/kexin ...

Jul, 2014 90 pages
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) - Forecast and Market ... -C treatment, Eli Lilly had to demonstrate the LDL-C lowering capacity of evacetrapib. SCOPE Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology ...

Jul, 2014 86 pages
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and Market ... in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during the acute phase of ACS, and as a once ...

Jul, 2014 60 pages
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and Market ... . It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin ...

Jul, 2014 60 pages
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast and Market ... to cangrelor in Japan. GlobalData assumes, for this forecast, that AstraZeneca will retain marketing privileges for cangrelor in Japan, where GlobalData expects cangrelor will ...

Jul, 2014 88 pages
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and Market ... US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along ...

Jul, 2014 59 pages
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast and Market ... medically and financially. GlobalData anticipates that Pfizer’s PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgen ...

Jul, 2014 85 pages
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and Market ... and financially. The Medicines Company launched its novel anticoagulant, Angiomax (bivalirudin), in the US in January 2001 following approval by the US FDA in December ...

Jul, 2014 59 pages
1 2 3 4 5 >
Skip to top